Enliven 制药 ELVN
$49.43 +$4.64 (+10.36%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $49.75 +0.65%
开盘$46.19
昨收$44.79
当日区间$44.55 – $49.66
成交量969.8K
市值$3.64B
市盈率（TTM）–
股息率–
ELVN 相关新闻
匹配 Enliven Therapeutics 或代码 ELVN 的头条新闻，按最新排序。
- LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 正面
- LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
- A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
- Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73 正面
- William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy Rating
- Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
- H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 正面
- Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67 正面
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80 正面
- Stifel Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $60
- Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $59
- JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 正面
- Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $62 正面
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60
暂无评论——快来第一个聊聊 ELVN。
登录后参与讨论。